Regulation & Compliance

A new FDA-cleared system offers hope against postpartum hemorrhage, the leading cause of maternal death, earning its maker a prestigious Edison Award.

Zywave's Spring 2026 release promises to slash administrative work with new AI agents, but can its execution live up to the ambitious vision for growth?

A new partnership aims to replace perception with performance data, allowing crypto projects to vet liquidity partners with unprecedented clarity.

As federal funding for psychedelic therapy surges, practitioners warn that a critical lack of patient preparation and integration support could undermine healing.

Responding to geopolitical risks, Telenor is launching a new company to provide a secure, nationally controlled cloud for Norway's most sensitive data.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

As SAP’s 2027 ECC support deadline looms, firms face a tough choice. New services offer a third way beyond the vendor's roadmap.

A new geological report confirms gold potential at Treasure Canyon, but for a company with no revenue, the path to riches is paved with high risk.

The new Spring 2026 platform moves beyond data storage, using AI to transform MedTech regulatory affairs into a strategic, high-speed execution engine.

Residents in Argyle, Nova Scotia demand an independent review, alleging a 'captured' process fast-tracking aquaculture leases for industry insiders.

Global anti-graft leaders converge to tackle digital corruption, implement a new EU directive, and forge a high-tech, collaborative front against graft.

A top European fertility network is rolling out AI to select embryos, promising higher success rates but sparking debate on the future of data-driven parenthood.

A new AI voice agent from Zibu promises to solve after-hours communication woes, reduce missed appointments, and alleviate doctor burnout. But can it stand out?

Phillips & Associates' 2026 Best Law Firms recognition spotlights its success in fighting workplace power abuse and its trauma-informed client approach.

The biotech's blockbuster Nasdaq debut provides crucial capital for its promising pipeline, offering new hope for patients with severe bleeding conditions.

Claire Elyse Brosseau launches an emergency legal bid to access assisted dying for mental illness, challenging Canada's repeated legislative delays.

Valion Bio's new General Counsel, a rare blend of scientist and lawyer, is poised to navigate its radiation drug through the FDA's complex Animal Rule.

Hundreds of teddy bears reveal a stark reality: nearly half of Albertans face sexual violence, and support services are overwhelmed. Can a new campaign help?

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

Prismm joins Jack Henry's network to help banks retain assets as unprecedented generational wealth transfer looms, threatening massive deposit flight.